Back to List View Graph View

Glucagon-like peptide-1 (GLP-1)

Glucagon-like peptide-1 (GLP-1) is a peptide hormone with important roles in glucose homeostasis and energy balance.

Where the papers sit

8 papers from the last 6 months study Glucagon-like peptide-1 (GLP-1) directly · updated from PubMed 27 Oct 2026

Study type 0 clinical trials · 4 observational · 3 human data · 1 preclinical

Themes 3 themes · 1 new direction

  • GLP-1 Therapeutics and Tolerability

    Peptide engineering is expanding GLP-1 activity toward GIP/glucagon triple agonism and receptor-guided delivery. Clinical attention centers on nausea, enteral feeding intolerance, and delayed small-bowel transit during GLP-1-based treatment. Metabolic stability and receptor specificity recur as design goals. The balance between stronger multi-receptor effects and gastrointestinal tolerability remains open.

    5 papers · 62.5%

  • GLP-1 Signaling in Bone

    GLP-1 and GIP are being examined as regulators of bone marrow and skeletal metabolism under hyperglycemia. GLP-1 influences bone marrow stromal-cell osteo-adipogenic fate through HIF-2-AKT signaling. This activity is linked to preservation of trabecular bone in glucocorticoid-induced osteoporosis. Whether these effects translate into broader treatment for metabolic bone loss remains unresolved.

    2 papers · 25%

  • Weight Loss After Bariatric Surgery

    Early weight loss after bariatric procedures is the central clinical endpoint. The focus is identifying predictors of suboptimal loss in people treated for obesity. Procedure-related and patient-level variation frame the analysis. The available work is predictive rather than mechanistic and does not establish a preferred intervention.

    1 papers · 12.5%

NEW DIRECTION

GLP-1 is repurposed as a receptor-guided intracellular delivery vehicle for targeted protein degradation

The multicomponent-stapled GLP-1 agent in GLP-1 receptor-positive cells was not used chiefly as a metabolic signaling agonist; instead, it retained receptor agonism while delivering a BRD4-directed PROTAC into cells and inducing selective intracellular BRD4 degradation. This gives GLP-1 a carrier and cell-selective drug-entry role, extending it beyond the set’s uses as a metabolic or tissue-signaling mediator and establishing a platform for receptor-guided protein degradation 42283322Jun.

Papers

The 8 papers from the last 6 months that study Glucagon-like peptide-1 (GLP-1) directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.

By theme

GLP-1 Therapeutics and Tolerability (5)
  1. Emerging risks of health optimisation: refractory nausea associated with peptide injections reported to contain retatrutide. BMJ case reports · 7 Oct 2026 PMID 42843917
  2. Elevated plasma glucagon-like Peptide-1 levels are associated with enteral feeding intolerance in traumatic brain injury. Clinical nutrition (Edinburgh, Scotland) · 3 Aug 2026 PMID 42546448
  3. Design of a metabolically-stable peptide therapeutic with triple-hormone-receptor agonist activity. Journal of computer-aided molecular design · 30 Jul 2026 PMID 42530676
  4. Association between GLP-1-based therapy and small-bowel transit time during capsule endoscopy: a prospective, multicentre, observational study. BMJ open gastroenterology · 15 Jul 2026 PMID 42457308
  5. Multicomponent Stapling of Glucagon-Like Peptide-1 Enables Receptor-Guided PROTAC Delivery. Angewandte Chemie (International ed. in English) · 12 Jun 2026 PMID 42283322
GLP-1 Signaling in Bone (2)
  1. Bone marrow responses to GLP-1 and GIP infusion under hyperglycaemic conditions. European journal of endocrinology · 19 Sept 2026 PMID 42762476
  2. GLP-1 regulates osteo-adipogenic fate of BMSCs via HIF-2-AKT signaling and supports trabecular bone in glucocorticoid-induced osteoporosis. Stem cell reports · 9 Jul 2026 PMID 42425087
Weight Loss After Bariatric Surgery (1)
  1. Incidence and Predictors of Suboptimal Early Weight Loss after Bariatric Procedures. Obesity surgery · 22 May 2026 PMID 42174245

By study type

Observational studies and case reports (4)
  1. Emerging risks of health optimisation: refractory nausea associated with peptide injections reported to contain retatrutide. BMJ case reports · 7 Oct 2026 PMID 42843917
  2. Elevated plasma glucagon-like Peptide-1 levels are associated with enteral feeding intolerance in traumatic brain injury. Clinical nutrition (Edinburgh, Scotland) · 3 Aug 2026 PMID 42546448
  3. Association between GLP-1-based therapy and small-bowel transit time during capsule endoscopy: a prospective, multicentre, observational study. BMJ open gastroenterology · 15 Jul 2026 PMID 42457308
  4. Incidence and Predictors of Suboptimal Early Weight Loss after Bariatric Procedures. Obesity surgery · 22 May 2026 PMID 42174245
Human data, design not indexed (3)
  1. Bone marrow responses to GLP-1 and GIP infusion under hyperglycaemic conditions. European journal of endocrinology · 19 Sept 2026 PMID 42762476
  2. Design of a metabolically-stable peptide therapeutic with triple-hormone-receptor agonist activity. Journal of computer-aided molecular design · 30 Jul 2026 PMID 42530676
  3. Multicomponent Stapling of Glucagon-Like Peptide-1 Enables Receptor-Guided PROTAC Delivery. Angewandte Chemie (International ed. in English) · 12 Jun 2026 PMID 42283322
Preclinical: animal, cell and lab studies (1)
  1. GLP-1 regulates osteo-adipogenic fate of BMSCs via HIF-2-AKT signaling and supports trabecular bone in glucocorticoid-induced osteoporosis. Stem cell reports · 9 Jul 2026 PMID 42425087